Steve,
There's not a lot of difference among the ARB's...all are weak antihypertensives that block the attatchment of angiotensin-2.
Probably Diovan, with the intese backing of its powerful maufacturer, Novartis, has more money to spend on doctor "advertising" <or bribes, if you are a cynic

> than does the lesser light, Boehringer-Ingleheim, the maker of Micardis.
The 60% figure for Diovan makes me scratch my head a bit; after all there are some strong competitors like Cozaar/ Hyzaar, Avapro, Atacand, Benicar and even the lowly Teveten along with the Micardis.
It seems almost impossible to me that in that horserace, Diovan could get 60% of the market?????? Are you sure?